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VASCULAR COGNITIVE IMPAIRMENT IN FIRST EVER 
ISCHEMIC STROKE SURVIVORS
O R I G I N A L  A R T I C L E
ABSTRACT
Objectives: Stroke and transient ischemic attacks (TIA) are highly prevalent in Pakistan. Post stroke dementia (PSD) 
is one of the main causes of dependency in survivors and includes any dementia after a stroke, irrespective of its 
cause, which includes vascular, degenerative, or mixed. Many Independent survivors have residual physical or cognitive 
deficits, or behavioral changes which can affect family life and have professional consequences. Study design: Cross 
sectional study at Department of Neurology CMC Hospital Larkana from Aug-2014 to Jan-2015 to find out frequency 
of dementia in first ever ischemic stroke patients, its severity and outcome. Methods: Study approved from ethical 
review committee of the institute. Patients 30-60 years of age, of either gender, previously non-demented with first 
episode of ischemic stroke were included in this study after informed consent. Patients of Hemorrhagic stroke, 
Parkinson’s disease, Terminal cancers and those on steroids were excluded. Stroke confirmed by CT scan brain/ MRI 
showing new infarcts. Dementia was defined as per MMSE dementia interview at baseline and 3 months of follow up. 
Score of <23 indicated cognitive impairment. Activity of daily living was assessed by AD8 screening interview. Score 
>2 indicated impairment in activity of daily living. Results: 120 patients were included in the study during 6 month 
period with mean age of 54(±3.4) years. Among them 74 were males and 46 were females. 52 (43.33%) patients 
had a lacunar stroke, 43(35.8%) a MCA infarct, 13(10.83%) with ACA infarct, 12 (10%) a posterior circulation stroke. 
Among vascular risk factors hypertension present in 32 (26%), diabetes in 22(18.3%), atrial fibrillation in 11(9.16%), 
previous myocardial infarction 10( 8.33%) and history of transient ischemic attack 34(28.33%). Their medical history, 
neurological deficit, activity of daily living, a blood screen and extent of vascular territory of the stroke were recorded.  
MMSE at 3 month of stroke follow up performed which revealed <23 score among 33(26%) patients. The activity of 
daily living was impaired among the demented patients. Recall, language and attention was impaired more than 
registration and orientation. Discussion: Patients with PSD have high mortality rates and are likely to be functionally 
impaired. The progressive decline of recall and forgetfulness observed in our study severely affect the activity of daily 
living. The best way to prevent dementia is preventing vascular risk factors and the stroke by medications and follow 
up. Conclusion: Stroke patients should be assessed with dementia and monitored regularly with structured MMSE and 
activity of daily living as part of routine check up  to prevent  mortality and morbidity in stroke survivors.
Key words: Dementia, AD8, MMSE, Lacunar infarct, PSD, Parkinsons disease, Cognitive impairment.
INTRODUCTION
Stroke is the major cause of physical disability in adults, 
the second most common cause of dementia, and the 
third leading cause of death (after coronary-artery 
diseases and cancers).2 Vascular cognitive impairment 
is decline caused by ischemic, hemorrhagic, or oligemic 
injury to the brain as a consequence of cerebrovascular  
disease.It is one of the main causes of dependency in 
survivors and includes any dementia after a stroke, 
irrespective of its cause, which includes vascular, 
degenerative, or mixed. A huge increase in prevalence 
and burden of PSD is likely to happen because of the 
decline in mortality after stroke and ageing of 
populations.1 The 24 year study also indicated that 
prevalence of Post stroke Dementia associated with 
lacunar stroke was 7 times higher than other types of 
stroke, including Intracerebral hemorrhage6. According 
to Nys et al., a high proportion of stroke survivors 
developed the cognitive impairment within 3 months of 
stroke. In hospital-based studies, the prevalence of 
PSD ranges from 5•9 to 32%.3,4 In another study 
prevalence of PSD was 27.2%3. In community-based 
studies with adjustment for age, the prevalence of 
dementia in people with a history of stroke is about 
30%, which is 3.5–5.8- times higher than in those who 
have not had stroke.3,5  The 5-year survival rate is 39% 
for patients with vascular dementia compared with 75% 
for age-matched controls. Vascular dementia is 
associated with a higher mortality rate than AD, 
presumably because of the coexistence of other 
atherosclerotic diseases. Stroke is one of the main 
causes of disability in the population. PSD is further 
worsening quality of life of patients as well as other 
people and relatives living with them. The data 
regarding this problem is not available from Pakistan. 
The aim of this study will be to determine the burden of 
dementia in patients of stroke so intervention can be 
made to help peoples with PSD to cope with daily life.
OBJECTIVE OF STUDY
To find out frequency of vascular cognitive impairment 
in first ever ischemic stroke survivors, its severity and 3 
months outcome.
METHODOLOGY
Cross-sectional study at Department of Neurology CMC 
Hospital, SMBBMU Larkana from Aug-2014 to 
Jan-2015. Cases fulfilling the DSM-5 criteria were 
included in the study after informed consent: Evidence 
of cognitive decline from a previous level of perfor-
mance in one or more cognitive domains. 
B.   The clinical features consistent with a vascular
     etiology as suggested by either of the following: 
     1) Cognitive deficits is temporally related to one or 
     more cerebrovascular events; 
     2) Decline is prominent in complex attention and 
     frontal executive functions.
C.   There is evidence of the presence of cerebrovascular
     disease 
D.   The symptoms are not better explained by another 
     brain disease or systemic disorder.
Data was collected for age, sex, smoking status, 
education level, vascular risk factors, area of infarct, 
neuropsychological assessment and activity of daily 
living by AD8 scoring system. Both the in-patients and 
outpatient cases were included. Data was collected by 
researcher himself and analysis was done on SPSS 
version19. Patients of 30-60 years of age, of either 
gender, previously non demented with first episode of 
ischemic stroke confirmed by CT/MRI were included 
after informed consent. While cases of Hemorrhagic  
stroke, old stroke, known cases of  Parkinson’s disease, 
neurodegenerative disorders( AD,LBD,FTD) or Terminal 
cancers were excluded from the study. All patients were 
put on stroke protocol and their medical history, 
neuropsychological assessment, activity of daily living, a 
blood screen ,cardiac screen, and  vascular involvment 
of the stroke were recorded.
RESULTS
Total 120 patients were included in the study during 6 
month period with mean age of 52(±3.4) years. Among 
them 74(61.6%) were males and 46(38.3%) were females.
There were 48(40%) of patients in  age range of 41-50 
years group and 40(33.3%) In 51-60 yand 32(26.6%) 
in 31-40 Years of age.
There were n=50(41.66% ) patients in matriculated group 
while n=49(41%) were graduate and n=21(17.5%) in 
uneducated group. 
Among total 120 patients 34(28.3%) patients were 
smokers.
There were more number of patients having lacunar 
stroke 52(42.2%), middle cerebral artery infarct
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Cirrhosis or end stage liver disease is destruction of 
normal liver parenchyma, replaced by regenerating 
nodules and scar tissue, due to various reasons 
common  causes includes HBV, HCV, and alcoholic liver 
disease. Hepatic Encephalopathy is present in about 
50-70% of all patients with cirrhosis.(1) Hepatic 
Encephalopathy is a complex neuropsychiatric syndrome 
associated with acute or chronic hepato- cellular failure 
and porto-systemic shunting of blood. It is one of the 
major complications of cirrhosis. Various neurotoxins 
have been known to involve in pathogenesis of hepatic 
encephalopathy. High levels of ammonia, glutamate, 
endogenous benzodiazepines, Gamma Amino butyric 
Acid (GABA) have been strongly associated with acute 
hepatic encephalopathy. 2 Among these, raised level of 
ammonia is thought to play a major role in pathogenesis 
of hepatic encephalopathy. 3,4 In hepatic encephalopat- 
hy the rate of ammonia metabolism decreases  and its 
permeability to blood brain barrier increases, resulting 
in elevated ammonia levels in brain with variable 
changes in blood. This mechanism is also supported by 
the fact that cirrhotic patients are sensitive to 
conditions associated with excess ammonia 
(constipation, protein overload, internal bleeding or 
sepsis).5 It also explains the reason why some patients 
have marginal elevation of arterial ammonia, despite 
hepatic encephalopathy.6 Therefore reduction in 
ammonia levels in the body is important treatment 
strategy.7 The L-ornithine L-Aspartate(LOLA) are salts of 
naturally occurring aminoacids ornithine and aspartate. 
They stimulate urea cycle and glutamine synthesis, 
which are major mechanisms of ammonia detoxification.8 
Over last 25 years, various studies were carried out 
regarding efficacy of LOLA in improvement of hepatic 
encephalopathy, showed controversial results. Blanco 
et al compared the standard treatment, with LOLA and 
concluded that LOLA was effective not only in reducing 
hyperammonemia and the severity of this disease, but 
also in improving the patient's perceived quality of life.9 
Sharma et al conducted a study in 2014and concluded 
that LOLA, probiotics and rifxamine were all superior to 
placebo, although this study was conducted on patients 
with minimal hepatic encephalopathy.10 A meta-analysis 
done in 2009 reviewed four studies and concluded that 
although use of LOLA was associated with decreasing 
serum ammonia levels, no clinical improvement was 
range: 6-47 micromol/l). In placebo group mean 
ammonia level was 112.28 micromole /dl on Day 
I.(Table:II) On Day III mean ammonia level in the trial 
group was 74.16 micromol/L. In placebo group mean 
ammonia level was 110.52 micromol/L .On comparison of 
serum ammonia levels before(day 1) and after (day 3) 
L-ornithine L aspartate therapy ,the difference was 
statistically significant in trial group(p value 0.0013)  while 
it was non significant in placebo group.(p value 0.124) 
(Table : II) To assess clinical improvement with LOLA, we 
used clinical grading of hepatic encephalopathy. In trial 
group, On Day I  10(20%) were in grade II, 17(34%) were 
in grade III and 23(46%) were in grade IV hepatic 
encephalopathy, while on day III 4(8%)  were in grade 
zero, 18(36%) were in I, 20(40% ) were in grade II, 
8(16%) in grade III and zero  were in grade IV hepatic 
encephalopathy. (Table:III) In placebo group on day I 
12(24%) % were in grade II, 19(38%) were in grade III, 
19(38%)  were in grade IV hepatic encephalopathy, while 
on day III no patient % was in grade zero,10(20%) were in 
grade I, 12 (24%) were in grade II, 18(36%)  were in 
grade III and 10(20%)  were in grade IV hepatic 
encephalopathy. On Day I clinical difference in grading of 
hepatic encephalopathy between two groups was 
statistically non significant. (p-values > 0.05) while on 
Day III, significant clinical improvement was observed p 
value < 0.05.(Table: III)
DISCUSSION
In developing countries like Pakistan cirrhosis liver is more 
prevalent compared to developed countries.17 In fact both 
hepatitis B virus (HBV) and hepatitis C virus (HCV) 
infections have become endemic in our community.18,19 
Hepatic Encephalopathy is a common neuro-psychiatric 
complication in CLD. High levels of ammonia in the body 
is a major cause of hepatic encephalopathy, that’s why 
most of the treatments are targeted against the 
detoxification of ammonia. L Ornithine L aspartate (LOLA) 
stimulates the urea cycle and ammonia utilization that’s 
why thought to be useful in acute hepatic encephalopathy. 
In our study, it was observed that the LOLA has beneficial 
effects not only in clinical improvement of encephalopathy 
but also obvious decrease in serum ammonia levels after 
infusion of LOLA. These results were comparable to other 
studies. Bai et al concluded after meta-analysis of 8 
randomized clinical trials including 646 patients that, 
LOLA was beneficial in both overt and minimal hepatic 
encephalopathy, causes both clinical and biochemical 
detoxification of ammonia.20 Another meta analysis done 
in 2011 supported the use of LOLA for neuro-psychiatric 
improvement as well as decreasing levels of ammonia.21
Although regional data is sparse however, it is necessary 
to identify two clinical trials. In 2011 Abid et al conducted 
a study in  Agha Khan university Hospital on 110 patients 
concluded that LOLA was safe and associated with rapid 
clinical improvement and shorter hospital stay.14 Ahmed et 
al conducted a study in in Shaikh Zyed hospital Lahore on 
80 patients in 2008 concluded that ornithine infusion 
was associated with rapid clinical recovery and decrease 
serum ammonia.13 Considering the results of our trial and 
other national and international studies and meta 
analysis, we can recommend use of LOLA as addition to 
other standard therapies of hepatic encephalopathy since 
ornithine therapy is safe, with mild side effects like 
nausea and vomiting and is easily available, can be given 
both orally and parenterally and does not adds significant 
cost to treatment of hepatic encephalopathy. Future 
studies should be directed towards comparison of 
efficacy L ornithine therapy with others drugs used for 
standard treatment of hepatic encephalopathy like 
lactitol, rifixamine, Zinc supplements and branch chain 
amino acids.
CONCLUSION
LOLA is effective in decreasing serum ammonia as well 
as causes clinical improvement in patients with hepatic 
encephalopathy. It can be recommended that LOLA 
may be used in the patients with hepatic 
encephalopathy especially when not responsive to 
standard treatment regimen.
Table I: Distribution of patients according to 
characteristics
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observed. But these studies were of small sample size 
and shorter follow ups.11 Another  meta-analysis done 
on three studies showed that LOLA therapy causes  
decrease in serum ammonia levels, and also clinical 
improvement.12 Moreover most of the available data 
assessed role of LOLA in minimal encephalopathy, not 
the over encephalopathy. In the review of local data, 
there are only two authentic large trials available.13,14 
Therefore due to absence of large studies, controversial 
existing data and paucity of local data, we conducted a 
study to observe effect of LOLA on clinical improvement 
in most stages of hepatic encephalopathy. 
MATERIAL & METHOD
After approval of Ethical review committee of Jinnah 
Medical and Dental College, a randomized, placebo- 
control trial was performed in medical department of 
Jinnah medical and dental college Hospital Korangi 
Karachi from July 2013 to June 2014. The trial was 
designed and reported according to CONSORT 
guidelines.15 An informed consent was taken before 
entry in the trial. Data was collected by Interns and 
residents of the ward, who were trained by the authors 
for this study through workshops and meetings. 
Patients > 18 years of age, admitted in medical ward, 
diagnosed with Chronic liver disease (CLD) due to any 
cause, having grade II to grade IV Hepatic 
Encephalopathy were included in the study after 
informed consent. CLD was diagnosed by common 
complications like ascites, gastro-oesophagal varices, 
with sonographic findings of shrunken liver, splenomegaly, 
portal vein size > 1 cm, deranged clotting profile and  
and inverse albumin /globulin ratio. Hepatic 
encephalopathy was diagnosed on the basis of 
confusion, drowsiness, restlessness, disorientation and 
asterixis without any altered explanation of these 
symptoms. Clinical grading of hepatic encephalopathy 
was done by West Haven’s criteria.16 Patient having 
sepsis, hepatorenal syndrome, acute/ chronic kidney 
disease were excluded from the study because they 
might affect ammonia levels. Hypoglycemia and 
respiratory failure was excluded by measuring random 
blood sugar and arterial blood gases. The estimated 
sample size was 102 patients, considering 500 annual 
admissions in our ward. The patients meeting inclusion 
criteria were randomly allocated into two groups with 50 
patients in each group. The Trial-Treatment group 
received L-Ornithine L-Aspartate; the Placebo group 
received normal saline. Both groups continued to 
receive all other standard supportive treatment 
including lactulose and metronidazole. The patients 
with precipitating factors such as infection, 
constipation, hypokalemia, dehydration, electrolyte 
imbalance, prolonged prothrombin time were treated 
accordingly. Performa was completed for each patient 
to record demographics, vitals, complete blood counts, 
liver function tests, prothrombin time, total proteins, 
electrolytes, serum ammonia, random blood glucose 
and renal status.  In addition, ultra-sound of the whole 
abdomen was also done, to assess the size of liver, 
spleen and portal vein. Trial-Treatment group received a 
daily intravenous infusion of 20 g (4 ampoules) 
L-Ornithine L-Aspartate (Inj HepaMerz, Brooks pharma) 
diluted in 250 ml of 5% dextrose water administered 
slowly over 4 hours for three consecutive days. The 
Placebo group received a daily administration of 250 ml 
normal saline over 4 hours for three consecutive days.  
It was ensured that the infusions were given at the 
same specified time to both groups of patients. About 5 
ml of blood of each patient was drawn on Day 1 and 
Day 3 under aseptic techniques, stored in rubber 
corked glass tubes for checking ammonia levels. The 
Tubes were frozen at 4 degrees centigrade temperature.  
The ammonia determination was performed according 
to the enzymatic determination of ammonia with 
glutamine dehydrogenase in a rapid and interference – 
free photomertric determination of NH4+ in native 
blood plasma. The testing was performed at a reliable 
laboratory of Karachi. Sample on Day 1, was collected 
as soon as a patient presented, before any treatment 
was started. The second sample was drawn on Day 3 
i.e. after the patient received three days of the 
Trial-Treatment or Placebo. Clinical improvement in 
hepatic encephalopathy was noted by West Haven’s 
criteria, on day 1 before LOLA infusion and on day III 
after infusion. Data was collected on the prescribed 
performa and analyzed using Statistical Package for 
Social Services (SPSS) V 17. Numerical data was 
recorded as mean and standard deviation, nominal data 
was recorded as frequency and percentage. Patients on 
treatment with Ornithine - Aspartate infusion and on 
placebo were compared by paired t-test. A p-value of < 
0.05 was considered statistically significant.
RESULT
Out of 102, two patients were discharged or referred 
before collection of data. The remaining patients 
completed study. Half of the patients (50), received 
L-Ornithine L-Aspartate (LOLA) and half received Placebo 
(50). In LOLA group 20(40%) were female and 30(60%) 
were male. In placebo group were 22(44%) female and 
28(56%) male. Mean age was 49.66+ 12.25 SD in trial 
group and 46.06 +9.83 SD in placebo group. Out of 100 
people 43 % had HCV, 22 % had HBV, 4 % were non B-C 
and 8 % had both B and C virus. (Table: I) On Day I mean 
ammonia was 105.2 micromol/l in trial group. (Normal 
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RESULTS
Total 120 patients were included in the study during 6 
month period with mean age of 52(±3.4) years. Among 
them 74(61.6%) were males and 46(38.3%) were females.
There were 48(40%) of patients in  age range of 41-50 
years group and 40(33.3%) In 51-60 yand 32(26.6%) 
in 31-40 Years of age.
There were n=50(41.66% ) patients in matriculated group 
while n=49(41%) were graduate and n=21(17.5%) in 
uneducated group. 
Among total 120 patients 34(28.3%) patients were 
smokers.
There were more number of patients having lacunar 
stroke 52(42.2%), middle cerebral artery infarct
42(25.9%), 12(10%) anterior cerebral artery infarcts 
and posterior cerebral artery infarcts while 2(1 .6%) had 
cortical or watershed infarct.
Hypertension was most common vascular risk factor 
which was present in 32(26%) while Diabetes mellitus 
in 22(18.3%), Atrial fibrillation in 11(9.16%), previous 
history of Myocardial Infarction in 10(8.33%) and 
Transient Ischemic Attack in 20(28.33%) of patients.
Mini mental status examination at 3 months follow up 
revealed <23 score among n=33(26%) patients and 8 
patients had score of less than 18.
Among the MMSE questionnaire Language, Attention 
and calculation was more impaired as compared to 
orientation, recall and registration.
Activity of daily living was assessed by AD8 scoring 
system which revealed trouble handling financial affairs, 
remembering appointments, using gadgets and 
problem in decision and thinking. Repetititon of 
questions, stories and statements was less frequent 
problem.
The male patients were more in number with associated 
mild cognitive impairment, mild, moderate or severe 
dementia as compared to female patients.
DISCUSSION
Among the 120 cases of first ever ischemic stroke <23 
score was present in n=33(26%) as assessed by Mini 
Mental status examination. There is progressive decline 
of recall and forgetfulness observed in our study. The 
stroke survivors had impaired activities of daily living. 
There were more number of hypertensive and diabetic 
patients in our study who developed the cognitive 
impairment. The best way to prevent dementia is to 
treat vascular risk factors and secondary prevention of 
stroke by medications and monitoring of lipids, blood 
pressure, blood sugar, cardiac profile, renal profile and 
cognition by MMSE. The study on 2,932 participants 
from Coronary Artery Risk Development in Young Adults 
study suggested that keeping weight, healthful diet, 
nonsmoking, physical activity, and controlling 
cholesterol, blood pressure, and fasting glucose were 
related to the better performance on cognition in later 
life.7 The study on patients with VCI of no-dementia 
suggested 3-month treatment of Ginkgo Biloba could 
improve the cognitive function as measured by MoCA 






World wide Prevalence Of Vascular Dementia
There are 31% dementia cases 3 months after stroke in 
USA while 58% cases of vascular dementia in Australia. In 
India prevalence is 20% annually.
CONCLUSION
Patients with PSD have high mortality rates and are likely 
to be functionally impaired. Both the demographic factors 
like age, education and occupation and vascular factors 
count for the high risk of post-stroke cognitive 
impairment. Stroke patients should be assessed with 
dementia and monitored regularly with structured MMSE 
and activity of daily living as part of routine check up to 
prevent  mortality and morbidity in stroke survivors.
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INTRODUCTION
Cirrhosis or end stage liver disease is destruction of 
normal liver parenchyma, replaced by regenerating 
nodules and scar tissue, due to various reasons 
common  causes includes HBV, HCV, and alcoholic liver 
disease. Hepatic Encephalopathy is present in about 
50-70% of all patients with cirrhosis.(1) Hepatic 
Encephalopathy is a complex neuropsychiatric syndrome 
associated with acute or chronic hepato- cellular failure 
and porto-systemic shunting of blood. It is one of the 
major complications of cirrhosis. Various neurotoxins 
have been known to involve in pathogenesis of hepatic 
encephalopathy. High levels of ammonia, glutamate, 
endogenous benzodiazepines, Gamma Amino butyric 
Acid (GABA) have been strongly associated with acute 
hepatic encephalopathy. 2 Among these, raised level of 
ammonia is thought to play a major role in pathogenesis 
of hepatic encephalopathy. 3,4 In hepatic encephalopat- 
hy the rate of ammonia metabolism decreases  and its 
permeability to blood brain barrier increases, resulting 
in elevated ammonia levels in brain with variable 
changes in blood. This mechanism is also supported by 
the fact that cirrhotic patients are sensitive to 
conditions associated with excess ammonia 
(constipation, protein overload, internal bleeding or 
sepsis).5 It also explains the reason why some patients 
have marginal elevation of arterial ammonia, despite 
hepatic encephalopathy.6 Therefore reduction in 
ammonia levels in the body is important treatment 
strategy.7 The L-ornithine L-Aspartate(LOLA) are salts of 
naturally occurring aminoacids ornithine and aspartate. 
They stimulate urea cycle and glutamine synthesis, 
which are major mechanisms of ammonia detoxification.8 
Over last 25 years, various studies were carried out 
regarding efficacy of LOLA in improvement of hepatic 
encephalopathy, showed controversial results. Blanco 
et al compared the standard treatment, with LOLA and 
concluded that LOLA was effective not only in reducing 
hyperammonemia and the severity of this disease, but 
also in improving the patient's perceived quality of life.9 
Sharma et al conducted a study in 2014and concluded 
that LOLA, probiotics and rifxamine were all superior to 
placebo, although this study was conducted on patients 
with minimal hepatic encephalopathy.10 A meta-analysis 
done in 2009 reviewed four studies and concluded that 
although use of LOLA was associated with decreasing 
serum ammonia levels, no clinical improvement was 
range: 6-47 micromol/l). In placebo group mean 
ammonia level was 112.28 micromole /dl on Day 
I.(Table:II) On Day III mean ammonia level in the trial 
group was 74.16 micromol/L. In placebo group mean 
ammonia level was 110.52 micromol/L .On comparison of 
serum ammonia levels before(day 1) and after (day 3) 
L-ornithine L aspartate therapy ,the difference was 
statistically significant in trial group(p value 0.0013)  while 
it was non significant in placebo group.(p value 0.124) 
(Table : II) To assess clinical improvement with LOLA, we 
used clinical grading of hepatic encephalopathy. In trial 
group, On Day I  10(20%) were in grade II, 17(34%) were 
in grade III and 23(46%) were in grade IV hepatic 
encephalopathy, while on day III 4(8%)  were in grade 
zero, 18(36%) were in I, 20(40% ) were in grade II, 
8(16%) in grade III and zero  were in grade IV hepatic 
encephalopathy. (Table:III) In placebo group on day I 
12(24%) % were in grade II, 19(38%) were in grade III, 
19(38%)  were in grade IV hepatic encephalopathy, while 
on day III no patient % was in grade zero,10(20%) were in 
grade I, 12 (24%) were in grade II, 18(36%)  were in 
grade III and 10(20%)  were in grade IV hepatic 
encephalopathy. On Day I clinical difference in grading of 
hepatic encephalopathy between two groups was 
statistically non significant. (p-values > 0.05) while on 
Day III, significant clinical improvement was observed p 
value < 0.05.(Table: III)
DISCUSSION
In developing countries like Pakistan cirrhosis liver is more 
prevalent compared to developed countries.17 In fact both 
hepatitis B virus (HBV) and hepatitis C virus (HCV) 
infections have become endemic in our community.18,19 
Hepatic Encephalopathy is a common neuro-psychiatric 
complication in CLD. High levels of ammonia in the body 
is a major cause of hepatic encephalopathy, that’s why 
most of the treatments are targeted against the 
detoxification of ammonia. L Ornithine L aspartate (LOLA) 
stimulates the urea cycle and ammonia utilization that’s 
why thought to be useful in acute hepatic encephalopathy. 
In our study, it was observed that the LOLA has beneficial 
effects not only in clinical improvement of encephalopathy 
but also obvious decrease in serum ammonia levels after 
infusion of LOLA. These results were comparable to other 
studies. Bai et al concluded after meta-analysis of 8 
randomized clinical trials including 646 patients that, 
LOLA was beneficial in both overt and minimal hepatic 
encephalopathy, causes both clinical and biochemical 
detoxification of ammonia.20 Another meta analysis done 
in 2011 supported the use of LOLA for neuro-psychiatric 
improvement as well as decreasing levels of ammonia.21
Although regional data is sparse however, it is necessary 
to identify two clinical trials. In 2011 Abid et al conducted 
a study in  Agha Khan university Hospital on 110 patients 
concluded that LOLA was safe and associated with rapid 
clinical improvement and shorter hospital stay.14 Ahmed et 
al conducted a study in in Shaikh Zyed hospital Lahore on 
80 patients in 2008 concluded that ornithine infusion 
was associated with rapid clinical recovery and decrease 
serum ammonia.13 Considering the results of our trial and 
other national and international studies and meta 
analysis, we can recommend use of LOLA as addition to 
other standard therapies of hepatic encephalopathy since 
ornithine therapy is safe, with mild side effects like 
nausea and vomiting and is easily available, can be given 
both orally and parenterally and does not adds significant 
cost to treatment of hepatic encephalopathy. Future 
studies should be directed towards comparison of 
efficacy L ornithine therapy with others drugs used for 
standard treatment of hepatic encephalopathy like 
lactitol, rifixamine, Zinc supplements and branch chain 
amino acids.
CONCLUSION
LOLA is effective in decreasing serum ammonia as well 
as causes clinical improvement in patients with hepatic 
encephalopathy. It can be recommended that LOLA 
may be used in the patients with hepatic 
encephalopathy especially when not responsive to 
standard treatment regimen.
Table I: Distribution of patients according to 
characteristics
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observed. But these studies were of small sample size 
and shorter follow ups.11 Another  meta-analysis done 
on three studies showed that LOLA therapy causes  
decrease in serum ammonia levels, and also clinical 
improvement.12 Moreover most of the available data 
assessed role of LOLA in minimal encephalopathy, not 
the over encephalopathy. In the review of local data, 
there are only two authentic large trials available.13,14 
Therefore due to absence of large studies, controversial 
existing data and paucity of local data, we conducted a 
study to observe effect of LOLA on clinical improvement 
in most stages of hepatic encephalopathy. 
MATERIAL & METHOD
After approval of Ethical review committee of Jinnah 
Medical and Dental College, a randomized, placebo- 
control trial was performed in medical department of 
Jinnah medical and dental college Hospital Korangi 
Karachi from July 2013 to June 2014. The trial was 
designed and reported according to CONSORT 
guidelines.15 An informed consent was taken before 
entry in the trial. Data was collected by Interns and 
residents of the ward, who were trained by the authors 
for this study through workshops and meetings. 
Patients > 18 years of age, admitted in medical ward, 
diagnosed with Chronic liver disease (CLD) due to any 
cause, having grade II to grade IV Hepatic 
Encephalopathy were included in the study after 
informed consent. CLD was diagnosed by common 
complications like ascites, gastro-oesophagal varices, 
with sonographic findings of shrunken liver, splenomegaly, 
portal vein size > 1 cm, deranged clotting profile and  
and inverse albumin /globulin ratio. Hepatic 
encephalopathy was diagnosed on the basis of 
confusion, drowsiness, restlessness, disorientation and 
asterixis without any altered explanation of these 
symptoms. Clinical grading of hepatic encephalopathy 
was done by West Haven’s criteria.16 Patient having 
sepsis, hepatorenal syndrome, acute/ chronic kidney 
disease were excluded from the study because they 
might affect ammonia levels. Hypoglycemia and 
respiratory failure was excluded by measuring random 
blood sugar and arterial blood gases. The estimated 
sample size was 102 patients, considering 500 annual 
admissions in our ward. The patients meeting inclusion 
criteria were randomly allocated into two groups with 50 
patients in each group. The Trial-Treatment group 
received L-Ornithine L-Aspartate; the Placebo group 
received normal saline. Both groups continued to 
receive all other standard supportive treatment 
including lactulose and metronidazole. The patients 
with precipitating factors such as infection, 
constipation, hypokalemia, dehydration, electrolyte 
imbalance, prolonged prothrombin time were treated 
accordingly. Performa was completed for each patient 
to record demographics, vitals, complete blood counts, 
liver function tests, prothrombin time, total proteins, 
electrolytes, serum ammonia, random blood glucose 
and renal status.  In addition, ultra-sound of the whole 
abdomen was also done, to assess the size of liver, 
spleen and portal vein. Trial-Treatment group received a 
daily intravenous infusion of 20 g (4 ampoules) 
L-Ornithine L-Aspartate (Inj HepaMerz, Brooks pharma) 
diluted in 250 ml of 5% dextrose water administered 
slowly over 4 hours for three consecutive days. The 
Placebo group received a daily administration of 250 ml 
normal saline over 4 hours for three consecutive days.  
It was ensured that the infusions were given at the 
same specified time to both groups of patients. About 5 
ml of blood of each patient was drawn on Day 1 and 
Day 3 under aseptic techniques, stored in rubber 
corked glass tubes for checking ammonia levels. The 
Tubes were frozen at 4 degrees centigrade temperature.  
The ammonia determination was performed according 
to the enzymatic determination of ammonia with 
glutamine dehydrogenase in a rapid and interference – 
free photomertric determination of NH4+ in native 
blood plasma. The testing was performed at a reliable 
laboratory of Karachi. Sample on Day 1, was collected 
as soon as a patient presented, before any treatment 
was started. The second sample was drawn on Day 3 
i.e. after the patient received three days of the 
Trial-Treatment or Placebo. Clinical improvement in 
hepatic encephalopathy was noted by West Haven’s 
criteria, on day 1 before LOLA infusion and on day III 
after infusion. Data was collected on the prescribed 
performa and analyzed using Statistical Package for 
Social Services (SPSS) V 17. Numerical data was 
recorded as mean and standard deviation, nominal data 
was recorded as frequency and percentage. Patients on 
treatment with Ornithine - Aspartate infusion and on 
placebo were compared by paired t-test. A p-value of < 
0.05 was considered statistically significant.
RESULT
Out of 102, two patients were discharged or referred 
before collection of data. The remaining patients 
completed study. Half of the patients (50), received 
L-Ornithine L-Aspartate (LOLA) and half received Placebo 
(50). In LOLA group 20(40%) were female and 30(60%) 
were male. In placebo group were 22(44%) female and 
28(56%) male. Mean age was 49.66+ 12.25 SD in trial 
group and 46.06 +9.83 SD in placebo group. Out of 100 
people 43 % had HCV, 22 % had HBV, 4 % were non B-C 
and 8 % had both B and C virus. (Table: I) On Day I mean 
ammonia was 105.2 micromol/l in trial group. (Normal 
INTRODUCTION
Stroke is the major cause of physical disability in adults, 
the second most common cause of dementia, and the 
third leading cause of death (after coronary-artery 
diseases and cancers).2 Vascular cognitive impairment 
is decline caused by ischemic, hemorrhagic, or oligemic 
injury to the brain as a consequence of cerebrovascular  
disease.It is one of the main causes of dependency in 
survivors and includes any dementia after a stroke, 
irrespective of its cause, which includes vascular, 
degenerative, or mixed. A huge increase in prevalence 
and burden of PSD is likely to happen because of the 
decline in mortality after stroke and ageing of 
populations.1 The 24 year study also indicated that 
prevalence of Post stroke Dementia associated with 
lacunar stroke was 7 times higher than other types of 
stroke, including Intracerebral hemorrhage6. According 
to Nys et al., a high proportion of stroke survivors 
developed the cognitive impairment within 3 months of 
stroke. In hospital-based studies, the prevalence of 
PSD ranges from 5•9 to 32%.3,4 In another study 
prevalence of PSD was 27.2%3. In community-based 
studies with adjustment for age, the prevalence of 
dementia in people with a history of stroke is about 
30%, which is 3.5–5.8- times higher than in those who 
have not had stroke.3,5  The 5-year survival rate is 39% 
for patients with vascular dementia compared with 75% 
for age-matched controls. Vascular dementia is 
associated with a higher mortality rate than AD, 
presumably because of the coexistence of other 
atherosclerotic diseases. Stroke is one of the main 
causes of disability in the population. PSD is further 
worsening quality of life of patients as well as other 
people and relatives living with them. The data 
regarding this problem is not available from Pakistan. 
The aim of this study will be to determine the burden of 
dementia in patients of stroke so intervention can be 
made to help peoples with PSD to cope with daily life.
OBJECTIVE OF STUDY
To find out frequency of vascular cognitive impairment 
in first ever ischemic stroke survivors, its severity and 3 
months outcome.
METHODOLOGY
Cross-sectional study at Department of Neurology CMC 
Hospital, SMBBMU Larkana from Aug-2014 to 
Jan-2015. Cases fulfilling the DSM-5 criteria were 
included in the study after informed consent: Evidence 
of cognitive decline from a previous level of perfor-
mance in one or more cognitive domains. 
B.   The clinical features consistent with a vascular
     etiology as suggested by either of the following: 
     1) Cognitive deficits is temporally related to one or 
     more cerebrovascular events; 
     2) Decline is prominent in complex attention and 
     frontal executive functions.
C.   There is evidence of the presence of cerebrovascular
     disease 
D.   The symptoms are not better explained by another 
     brain disease or systemic disorder.
Data was collected for age, sex, smoking status, 
education level, vascular risk factors, area of infarct, 
neuropsychological assessment and activity of daily 
living by AD8 scoring system. Both the in-patients and 
outpatient cases were included. Data was collected by 
researcher himself and analysis was done on SPSS 
version19. Patients of 30-60 years of age, of either 
gender, previously non demented with first episode of 
ischemic stroke confirmed by CT/MRI were included 
after informed consent. While cases of Hemorrhagic  
stroke, old stroke, known cases of  Parkinson’s disease, 
neurodegenerative disorders( AD,LBD,FTD) or Terminal 
cancers were excluded from the study. All patients were 
put on stroke protocol and their medical history, 
neuropsychological assessment, activity of daily living, a 
blood screen ,cardiac screen, and  vascular involvment 
of the stroke were recorded.
RESULTS
Total 120 patients were included in the study during 6 
month period with mean age of 52(±3.4) years. Among 
them 74(61.6%) were males and 46(38.3%) were females.
There were 48(40%) of patients in  age range of 41-50 
years group and 40(33.3%) In 51-60 yand 32(26.6%) 
in 31-40 Years of age.
There were n=50(41.66% ) patients in matriculated group 
while n=49(41%) were graduate and n=21(17.5%) in 
uneducated group. 
Among total 120 patients 34(28.3%) patients were 
smokers.
There were more number of patients having lacunar 
stroke 52(42.2%), middle cerebral artery infarct
42(25.9%), 12(10%) anterior cerebral artery infarcts 
and posterior cerebral artery infarcts while 2(1 .6%) had 
cortical or watershed infarct.
Hypertension was most common vascular risk factor 
which was present in 32(26%) while Diabetes mellitus 
in 22(18.3%), Atrial fibrillation in 11(9.16%), previous 
history of Myocardial Infarction in 10(8.33%) and 
Transient Ischemic Attack in 20(28.33%) of patients.
Mini mental status examination at 3 months follow up 
revealed <23 score among n=33(26%) patients and 8 
patients had score of less than 18.
Among the MMSE questionnaire Language, Attention 
and calculation was more impaired as compared to 
orientation, recall and registration.
Activity of daily living was assessed by AD8 scoring 
system which revealed trouble handling financial affairs, 
remembering appointments, using gadgets and 
problem in decision and thinking. Repetititon of 
questions, stories and statements was less frequent 
problem.
The male patients were more in number with associated 
mild cognitive impairment, mild, moderate or severe 
dementia as compared to female patients.
DISCUSSION
Among the 120 cases of first ever ischemic stroke <23 
score was present in n=33(26%) as assessed by Mini 
Mental status examination. There is progressive decline 
of recall and forgetfulness observed in our study. The 
stroke survivors had impaired activities of daily living. 
There were more number of hypertensive and diabetic 
patients in our study who developed the cognitive 
impairment. The best way to prevent dementia is to 
treat vascular risk factors and secondary prevention of 
stroke by medications and monitoring of lipids, blood 
pressure, blood sugar, cardiac profile, renal profile and 
cognition by MMSE. The study on 2,932 participants 
from Coronary Artery Risk Development in Young Adults 
study suggested that keeping weight, healthful diet, 
nonsmoking, physical activity, and controlling 
cholesterol, blood pressure, and fasting glucose were 
related to the better performance on cognition in later 
life.7 The study on patients with VCI of no-dementia 
suggested 3-month treatment of Ginkgo Biloba could 
improve the cognitive function as measured by MoCA 
scores and the cerebral blood flow8.
World wide Prevalence Of Vascular Dementia
There are 31% dementia cases 3 months after stroke in 
USA while 58% cases of vascular dementia in Australia. In 
India prevalence is 20% annually.
CONCLUSION
Patients with PSD have high mortality rates and are likely 
to be functionally impaired. Both the demographic factors 
like age, education and occupation and vascular factors 
count for the high risk of post-stroke cognitive 
impairment. Stroke patients should be assessed with 
dementia and monitored regularly with structured MMSE 
and activity of daily living as part of routine check up to 
prevent  mortality and morbidity in stroke survivors.
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INTRODUCTION
Cirrhosis or end stage liver disease is destruction of 
normal liver parenchyma, replaced by regenerating 
nodules and scar tissue, due to various reasons 
common  causes includes HBV, HCV, and alcoholic liver 
disease. Hepatic Encephalopathy is present in about 
50-70% of all patients with cirrhosis.(1) Hepatic 
Encephalopathy is a complex neuropsychiatric syndrome 
associated with acute or chronic hepato- cellular failure 
and porto-systemic shunting of blood. It is one of the 
major complications of cirrhosis. Various neurotoxins 
have been known to involve in pathogenesis of hepatic 
encephalopathy. High levels of ammonia, glutamate, 
endogenous benzodiazepines, Gamma Amino butyric 
Acid (GABA) have been strongly associated with acute 
hepatic encephalopathy. 2 Among these, raised level of 
ammonia is thought to play a major role in pathogenesis 
of hepatic encephalopathy. 3,4 In hepatic encephalopat- 
hy the rate of ammonia metabolism decreases  and its 
permeability to blood brain barrier increases, resulting 
in elevated ammonia levels in brain with variable 
changes in blood. This mechanism is also supported by 
the fact that cirrhotic patients are sensitive to 
conditions associated with excess ammonia 
(constipation, protein overload, internal bleeding or 
sepsis).5 It also explains the reason why some patients 
have marginal elevation of arterial ammonia, despite 
hepatic encephalopathy.6 Therefore reduction in 
ammonia levels in the body is important treatment 
strategy.7 The L-ornithine L-Aspartate(LOLA) are salts of 
naturally occurring aminoacids ornithine and aspartate. 
They stimulate urea cycle and glutamine synthesis, 
which are major mechanisms of ammonia detoxification.8 
Over last 25 years, various studies were carried out 
regarding efficacy of LOLA in improvement of hepatic 
encephalopathy, showed controversial results. Blanco 
et al compared the standard treatment, with LOLA and 
concluded that LOLA was effective not only in reducing 
hyperammonemia and the severity of this disease, but 
also in improving the patient's perceived quality of life.9 
Sharma et al conducted a study in 2014and concluded 
that LOLA, probiotics and rifxamine were all superior to 
placebo, although this study was conducted on patients 
with minimal hepatic encephalopathy.10 A meta-analysis 
done in 2009 reviewed four studies and concluded that 
although use of LOLA was associated with decreasing 
serum ammonia levels, no clinical improvement was 
range: 6-47 micromol/l). In placebo group mean 
ammonia level was 112.28 micromole /dl on Day 
I.(Table:II) On Day III mean ammonia level in the trial 
group was 74.16 micromol/L. In placebo group mean 
ammonia level was 110.52 micromol/L .On comparison of 
serum ammonia levels before(day 1) and after (day 3) 
L-ornithine L aspartate therapy ,the difference was 
statistically significant in trial group(p value 0.0013)  while 
it was non significant in placebo group.(p value 0.124) 
(Table : II) To assess clinical improvement with LOLA, we 
used clinical grading of hepatic encephalopathy. In trial 
group, On Day I  10(20%) were in grade II, 17(34%) were 
in grade III and 23(46%) were in grade IV hepatic 
encephalopathy, while on day III 4(8%)  were in grade 
zero, 18(36%) were in I, 20(40% ) were in grade II, 
8(16%) in grade III and zero  were in grade IV hepatic 
encephalopathy. (Table:III) In placebo group on day I 
12(24%) % were in grade II, 19(38%) were in grade III, 
19(38%)  were in grade IV hepatic encephalopathy, while 
on day III no patient % was in grade zero,10(20%) were in 
grade I, 12 (24%) were in grade II, 18(36%)  were in 
grade III and 10(20%)  were in grade IV hepatic 
encephalopathy. On Day I clinical difference in grading of 
hepatic encephalopathy between two groups was 
statistically non significant. (p-values > 0.05) while on 
Day III, significant clinical improvement was observed p 
value < 0.05.(Table: III)
DISCUSSION
In developing countries like Pakistan cirrhosis liver is more 
prevalent compared to developed countries.17 In fact both 
hepatitis B virus (HBV) and hepatitis C virus (HCV) 
infections have become endemic in our community.18,19 
Hepatic Encephalopathy is a common neuro-psychiatric 
complication in CLD. High levels of ammonia in the body 
is a major cause of hepatic encephalopathy, that’s why 
most of the treatments are targeted against the 
detoxification of ammonia. L Ornithine L aspartate (LOLA) 
stimulates the urea cycle and ammonia utilization that’s 
why thought to be useful in acute hepatic encephalopathy. 
In our study, it was observed that the LOLA has beneficial 
effects not only in clinical improvement of encephalopathy 
but also obvious decrease in serum ammonia levels after 
infusion of LOLA. These results were comparable to other 
studies. Bai et al concluded after meta-analysis of 8 
randomized clinical trials including 646 patients that, 
LOLA was beneficial in both overt and minimal hepatic 
encephalopathy, causes both clinical and biochemical 
detoxification of ammonia.20 Another meta analysis done 
in 2011 supported the use of LOLA for neuro-psychiatric 
improvement as well as decreasing levels of ammonia.21
Although regional data is sparse however, it is necessary 
to identify two clinical trials. In 2011 Abid et al conducted 
a study in  Agha Khan university Hospital on 110 patients 
concluded that LOLA was safe and associated with rapid 
clinical improvement and shorter hospital stay.14 Ahmed et 
al conducted a study in in Shaikh Zyed hospital Lahore on 
80 patients in 2008 concluded that ornithine infusion 
was associated with rapid clinical recovery and decrease 
serum ammonia.13 Considering the results of our trial and 
other national and international studies and meta 
analysis, we can recommend use of LOLA as addition to 
other standard therapies of hepatic encephalopathy since 
ornithine therapy is safe, with mild side effects like 
nausea and vomiting and is easily available, can be given 
both orally and parenterally and does not adds significant 
cost to treatment of hepatic encephalopathy. Future 
studies should be directed towards comparison of 
efficacy L ornithine therapy with others drugs used for 
standard treatment of hepatic encephalopathy like 
lactitol, rifixamine, Zinc supplements and branch chain 
amino acids.
CONCLUSION
LOLA is effective in decreasing serum ammonia as well 
as causes clinical improvement in patients with hepatic 
encephalopathy. It can be recommended that LOLA 
may be used in the patients with hepatic 
encephalopathy especially when not responsive to 
standard treatment regimen.
Table I: Distribution of patients according to 
characteristics
2 1 V O L .  1 0  ( 3 )  J U L   -   S E P T   2 0 1 5P A K I S T A N  J O U R N A L  O F  N E U R O L O G I C A L  S C I E N C E S
observed. But these studies were of small sample size 
and shorter follow ups.11 Another  meta-analysis done 
on three studies showed that LOLA therapy causes  
decrease in serum ammonia levels, and also clinical 
improvement.12 Moreover most of the available data 
assessed role of LOLA in minimal encephalopathy, not 
the over encephalopathy. In the review of local data, 
there are only two authentic large trials available.13,14 
Therefore due to absence of large studies, controversial 
existing data and paucity of local data, we conducted a 
study to observe effect of LOLA on clinical improvement 
in most stages of hepatic encephalopathy. 
MATERIAL & METHOD
After approval of Ethical review committee of Jinnah 
Medical and Dental College, a randomized, placebo- 
control trial was performed in medical department of 
Jinnah medical and dental college Hospital Korangi 
Karachi from July 2013 to June 2014. The trial was 
designed and reported according to CONSORT 
guidelines.15 An informed consent was taken before 
entry in the trial. Data was collected by Interns and 
residents of the ward, who were trained by the authors 
for this study through workshops and meetings. 
Patients > 18 years of age, admitted in medical ward, 
diagnosed with Chronic liver disease (CLD) due to any 
cause, having grade II to grade IV Hepatic 
Encephalopathy were included in the study after 
informed consent. CLD was diagnosed by common 
complications like ascites, gastro-oesophagal varices, 
with sonographic findings of shrunken liver, splenomegaly, 
portal vein size > 1 cm, deranged clotting profile and  
and inverse albumin /globulin ratio. Hepatic 
encephalopathy was diagnosed on the basis of 
confusion, drowsiness, restlessness, disorientation and 
asterixis without any altered explanation of these 
symptoms. Clinical grading of hepatic encephalopathy 
was done by West Haven’s criteria.16 Patient having 
sepsis, hepatorenal syndrome, acute/ chronic kidney 
disease were excluded from the study because they 
might affect ammonia levels. Hypoglycemia and 
respiratory failure was excluded by measuring random 
blood sugar and arterial blood gases. The estimated 
sample size was 102 patients, considering 500 annual 
admissions in our ward. The patients meeting inclusion 
criteria were randomly allocated into two groups with 50 
patients in each group. The Trial-Treatment group 
received L-Ornithine L-Aspartate; the Placebo group 
received normal saline. Both groups continued to 
receive all other standard supportive treatment 
including lactulose and metronidazole. The patients 
with precipitating factors such as infection, 
constipation, hypokalemia, dehydration, electrolyte 
imbalance, prolonged prothrombin time were treated 
accordingly. Performa was completed for each patient 
to record demographics, vitals, complete blood counts, 
liver function tests, prothrombin time, total proteins, 
electrolytes, serum ammonia, random blood glucose 
and renal status.  In addition, ultra-sound of the whole 
abdomen was also done, to assess the size of liver, 
spleen and portal vein. Trial-Treatment group received a 
daily intravenous infusion of 20 g (4 ampoules) 
L-Ornithine L-Aspartate (Inj HepaMerz, Brooks pharma) 
diluted in 250 ml of 5% dextrose water administered 
slowly over 4 hours for three consecutive days. The 
Placebo group received a daily administration of 250 ml 
normal saline over 4 hours for three consecutive days.  
It was ensured that the infusions were given at the 
same specified time to both groups of patients. About 5 
ml of blood of each patient was drawn on Day 1 and 
Day 3 under aseptic techniques, stored in rubber 
corked glass tubes for checking ammonia levels. The 
Tubes were frozen at 4 degrees centigrade temperature.  
The ammonia determination was performed according 
to the enzymatic determination of ammonia with 
glutamine dehydrogenase in a rapid and interference – 
free photomertric determination of NH4+ in native 
blood plasma. The testing was performed at a reliable 
laboratory of Karachi. Sample on Day 1, was collected 
as soon as a patient presented, before any treatment 
was started. The second sample was drawn on Day 3 
i.e. after the patient received three days of the 
Trial-Treatment or Placebo. Clinical improvement in 
hepatic encephalopathy was noted by West Haven’s 
criteria, on day 1 before LOLA infusion and on day III 
after infusion. Data was collected on the prescribed 
performa and analyzed using Statistical Package for 
Social Services (SPSS) V 17. Numerical data was 
recorded as mean and standard deviation, nominal data 
was recorded as frequency and percentage. Patients on 
treatment with Ornithine - Aspartate infusion and on 
placebo were compared by paired t-test. A p-value of < 
0.05 was considered statistically significant.
RESULT
Out of 102, two patients were discharged or referred 
before collection of data. The remaining patients 
completed study. Half of the patients (50), received 
L-Ornithine L-Aspartate (LOLA) and half received Placebo 
(50). In LOLA group 20(40%) were female and 30(60%) 
were male. In placebo group were 22(44%) female and 
28(56%) male. Mean age was 49.66+ 12.25 SD in trial 
group and 46.06 +9.83 SD in placebo group. Out of 100 
people 43 % had HCV, 22 % had HBV, 4 % were non B-C 
and 8 % had both B and C virus. (Table: I) On Day I mean 









31% with demenia 3 months 57% . 1 year after
24% , 3 months
47.3% ,  3  months
58.9%, 5 years
44% 3 months after stroke








19.3% with dementia at 10 years
follow-up
39% , 1 month after
58% ,1 year after stroke
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